2016-2026年自體免疫疾病領域的合作與授權合約

Autoimmune Collaboration and Licensing Deals 2016-2026

出版日期: 2026年10月01日 | 出版商:

Current Partnering | 英文 550+ Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

我們將利用 1,066 項現有合作與許可協議的信息，了解自體免疫疾病領域合作的現狀。

《2016-2026 年自體免疫合作與授權交易》提供了有關自體免疫疾病領域資產、技術和開發計畫的 1,066 項合作與授權協議的全面資訊。

自體免疫疾病是生命科學領域廣泛且活躍的合作領域，涵蓋多種治療標靶、研發階段、技術和交易結構。

本報告將這些趨勢匯總到一個資源中，使用戶能夠了解哪些公司正在合作、哪些因素推動了交易、交易結構是什麼、披露了哪些財務條款，以及合作活動如何因自體免疫疾病目標和技術而異。

這份報告不只是簡單地列出了交易清單；它將全面的市場交易分析與詳細的財務基準、主要交易商的信息、個別交易記錄以及公開的合約文件相結合。

本報告為參與自體免疫疾病領域合作的業務發展、許可、研究和評估、公司策略、研發策略、競爭情報分析和法律團隊提供了實用的資訊來源和基準資源。

了解自體免疫疾病領域的合作趨勢。

本報告分析了2016年至2026年自體免疫疾病領域的交易情況，內容包括：

自體免疫疾病領域合作活動的年度趨勢
按交易類型分類的交易趨勢
產業部門
合作關係發展階段
技術類型
自體免疫疾病的治療標靶
自體免疫疾病領域最活躍的交易商
根據已披露的交易金額，主要交易
自體免疫疾病領域合作活動的趨勢
這使用戶能夠了解他們的活動集中在哪些方面，並識別出吸引合作興趣的公司、技術、開發階段和治療目標。
與自體免疫疾病相關的交易的財務基準
與自體免疫疾病相關的交易的經濟條款可能會因資產、開發階段、技術、授予的權利以及交易的整體結構而有很大差異。

本報告對已揭露的財務狀況進行了詳細分析，包括以下項目：

交易總額
預付款
里程碑付款
版稅率
此外，透過更詳細地審查個別交易，我們可以了解所揭露的經濟狀況背後的情況。
這樣，使用者在創造內部基準、評估商業機會或洽談合作關係時，就能獲得現實世界的基準。
財務基準只有在結合類似交易的結構和情況進行分析時才最有價值，而非孤立地看待其平均值。本報告提供了理解相關背景所需的更廣泛的交易資訊。
確定自體免疫疾病領域的關鍵交易商和有潛力的合作夥伴。
本報告列出了自體免疫疾病領域交易最活躍的公司，並提供了詳盡的交易歷史記錄，以便用戶可以調查其合作活動。

這有助於用戶識別以下內容：

積極尋求自體免疫疾病領域商機的公司
潛在的許可和合作研究夥伴
我們在特定治療領域反覆合作的組織
積極參與開發過程的公司
對特定技術或方法表現出興趣的交易商
競爭對手採取類似的外部創新策略
對於尋求在自體免疫疾病相關資產和技術方面擁有合作夥伴的公司而言，過去的交易歷史可以提供寶貴的見解，了解哪些組織對類似的機會表現出了真正的興趣。
我們將每種治療標靶的交易進行比較。
自體免疫疾病領域並非單一、同質性的合作市場。
本報告對自體免疫疾病的每個治療標靶進行了分析，使用戶能夠研究自體免疫疾病各個領域合作活動的差異，並確定與特定項目和策略關注事項最相關的交易。
這樣一來，使用者就可以專注於與自身機會最相關的交易子集，而不是簡單地對各種自體免疫疾病進行基準測試。
我們將了解與自體免疫疾病相關的合約結構。
本報告涵蓋合作研究、授權和其他合作關係，使用戶能夠檢驗各公司在自體免疫疾病相關資產和技術方面建立的關係。

根據交易詳情和資訊披露，用戶可以調查以下方面：

授予和保留的權利
研發職責
授權權
獨家版權
區域權利
智慧財產
負責開發和監管
商業化權利
金錢補償
里程碑和版稅
管治
合約期限和終止條款
這些例子對於考慮與新型自體免疫疾病相關的合作的適當結構將很有幫助。
從實際合約文件中學習
本報告提供了公開可取得的選定自體免疫疾病相關交易的合約文件。

這些合約揭露的資訊遠比簡單的標題公告詳細得多，有助於用戶了解公司如何記錄以下內容：

權利範圍
發展義務
智慧財產
獨家版權
財務狀況
里程碑觸發條件
特許權使用費規定
商業化權利
合約終止及其他談判事項
對於準備和談判與自體免疫疾病相關的合作研究或許可協議的團隊來說，獲取實際的合約措辭可以提供關於類似交易實際結構方式的寶貴見解。
自體免疫疾病相關交易綜合目錄
該報告包含一份全面的目錄，收錄了 1,066 項與自體免疫疾病相關的合作研究和許可協議，為識別相關領先提供了詳細的資訊來源。

在以下條件下可以查看交易記錄：

公司
技術類型
治療標靶
合約揭露狀態
每筆交易都與其底層交易記錄相關聯，從而可以存取詳細的交易資訊和相關的合約文件（如有）。
你會向哪些人推薦這份報告？
業務拓展與授權團隊
識別與自體免疫疾病相關的類似交易、潛在的未來合作關係以及相關的交易結構。
探勘與評估團隊
我們確定哪些公司正在積極探索特定自體免疫疾病標靶、技術和開發階段的機會。
尋求合作夥伴的生技公司
找出對類似自體免疫疾病相關資產和技術表現出明確興趣的組織。
企業策略與研發策略團隊
我們將了解競爭對手和潛在合作夥伴如何透過外部創新來建立自體免疫疾病相關產品線。
競爭情報與市場分析團隊
我們按公司、開發階段、技術和治療目標追蹤趨勢，以了解不斷變化的合作夥伴關係的優先事項。
法律及交易團隊
我們將仔細審查公開的合約和以往的合約結構，以幫助您準備和談判交易。
我們將市場範圍內的自體免疫疾病資訊轉化為針對特定公司的洞察。
符合資格的客戶將收到 Current Partnering 的報告，以及為高階主管量身訂製的合作關係簡報。
本次簡報將運用與自體免疫疾病相關的基礎交易訊息，來分析您自己的資產、技術、目標或合作目標。
如有需要，我們可以提供相關的類似交易、有潛力的合作夥伴候選人、競爭對手的活動、發展階段分析、交易結構、財務基準、忠誠度分析、合約見解以及其他專門為您選擇的資訊。
請索取樣本或聯絡 Current Partnering 討論本報告的內容以及我們是否可以為貴公司提供客製化分析。

依自體免疫疾病的治療標靶進行交易
交易目錄
交易目錄 -自體免疫相關交易依公司名稱排序（A-Z）
交易目錄 - 按技術類型分類的自體免疫疾病相關交易
交易類型的定義
關於生物製藥研究
Current Partnering
Current Agreements
理想合作夥伴近期報告標題

簡介目錄

Product Code: CP2228

Understand the autoimmune partnering landscape using intelligence from 1,066 real-world collaboration and licensing deals.

Autoimmune Collaboration and Licensing Deals 2016-2026 provides comprehensive intelligence on 1,066 partnering deals involving autoimmune assets, technologies and development programs.

Autoimmune disease represents a broad and active area of life sciences partnering, encompassing multiple therapeutic targets, development stages, technologies and deal structures.

The report brings this activity together in one resource, enabling users to understand who is partnering, what is attracting deal activity, how transactions are structured, what financial terms have been disclosed and how partnering activity differs across autoimmune targets and technologies.

Rather than simply providing a list of transactions, the report combines market-wide deal analysis with detailed financial benchmarking, leading dealmaker intelligence, individual transaction records and access to publicly available contract documents where available.

It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, competitive intelligence and legal teams involved in autoimmune partnering.

Understand the autoimmune partnering landscape

The report analyzes autoimmune dealmaking from 2016 to 2026, including:

Trends in autoimmune partnering activity by year
Deal activity by deal type
Industry sector
Stage of development at the time of partnering
Technology type
Autoimmune therapeutic target
Most active autoimmune dealmakers
Leading deals by disclosed value
How autoimmune partnering activity is evolving
This enables users to understand where activity is concentrated and identify the companies, technologies, development stages and therapeutic targets attracting partnering interest.
Benchmark autoimmune deal financials
The economics of autoimmune deals can vary significantly according to the asset, development stage, technology, rights granted and overall structure of the transaction.

The report provides dedicated analysis of disclosed financial terms, including:

Headline deal values
Upfront payments
Milestone payments
Royalty rates
Individual transactions can then be investigated in greater depth to understand the context behind the disclosed economics.
This provides users with real-world reference points when preparing internal benchmarks, evaluating opportunities or entering partnering discussions.
Financial benchmarks are most valuable when considered alongside the structure and circumstances of comparable deals rather than as standalone averages, and the report provides the wider transaction intelligence needed to establish that context.
Identify leading autoimmune dealmakers and prospective partners
The report identifies the most active companies in autoimmune dealmaking and provides extensive transaction histories that enable users to investigate their partnering activity.

This can help users identify:

Companies actively seeking autoimmune opportunities
Potential licensing and collaboration partners
Organizations repeatedly partnering in particular therapeutic areas
Companies active at relevant stages of development
Dealmakers showing interest in specific technologies or approaches
Competitors pursuing similar external innovation strategies
For companies seeking to partner an autoimmune asset or technology, previous deal activity can provide valuable evidence of which organizations have demonstrated a genuine appetite for comparable opportunities.
Compare deals across therapeutic targets
Autoimmune is not a single homogeneous partnering market.
The report provides analysis by autoimmune therapeutic target, enabling users to investigate differences in partnering activity across individual areas of autoimmune disease and identify transactions most relevant to a particular program or strategic interest.
This helps users move beyond broad autoimmune benchmarks and focus on the subset of transactions most relevant to their own opportunity.
Understand how autoimmune agreements are structured
The report includes collaboration, licensing and other partnering transactions, enabling users to examine how companies have structured relationships around autoimmune assets and technologies.

Depending on the transaction and available disclosure, users can investigate areas including:

Rights granted and retained
Research and development responsibilities
Licensing rights
Exclusivity
Geographic rights
Intellectual property
Development and regulatory responsibilities
Commercialization rights
Financial consideration
Milestones and royalties
Governance
Term and termination provisions
These real-world examples provide useful reference points when considering the appropriate structure for a new autoimmune partnership.
Learn from real-world contract documents
Where publicly available, the report provides access to underlying contract documents for selected autoimmune transactions.

These agreements can reveal substantially more detail than headline announcements alone, helping users understand how companies have documented areas such as:

Scope of rights
Development obligations
Intellectual property
Exclusivity
Financial terms
Milestone triggers
Royalty provisions
Commercialization rights
Termination and other negotiated provisions
For teams preparing or negotiating an autoimmune collaboration or licensing transaction, access to real agreement language provides valuable insight into how comparable deals have been structured in practice.
Comprehensive autoimmune deal directory
The report includes a comprehensive directory of 1,066 autoimmune collaboration and licensing deals, providing a detailed resource for identifying relevant precedent transactions.

Deals can be reviewed by:

Company
Technology type
Therapeutic target
Contract availability
Individual transactions are linked to their underlying deal records, providing a route to further deal information and associated contract documentation where available.
Who should use this report?
Business Development and Licensing teams
Identify comparable autoimmune transactions, prospective partners and relevant deal structures.
Search and Evaluation teams
Understand which companies are actively seeking opportunities across particular autoimmune targets, technologies and stages of development.
Biotechnology Companies Seeking Partners
Identify organizations with demonstrated interest in comparable autoimmune assets and technologies.
Corporate and R&D Strategy teams
Understand how competitors and potential partners are building autoimmune pipelines through external innovation.
Competitive and Market Intelligence teams
Track activity by company, development stage, technology and therapeutic target to understand evolving partnering priorities.
Legal and Transaction teams
Review publicly available contracts and precedent agreement structures to support transaction preparation and negotiation.
Turn market-wide autoimmune intelligence into company-specific insight
For qualifying customers, Current Partnering can also provide a Customized Executive Partnering Briefing alongside the report.
The briefing applies the underlying autoimmune deal intelligence to the customer's own asset, technology, target or partnering objectives.
Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, development-stage analysis, deal structures, financial benchmarks, royalty analysis, contract insights and other intelligence selected specifically for the client's situation.
Request a sample or contact Current Partnering to discuss the report and whether a customized analysis can be provided for your organization.